MELASMA: TRATAMENTO E SUAS IMPLICAÇÕES ESTÉTICAS

Kledson Lopes Barbosa, Monique Ribeiro Mota Guedes

Resumo


O melasma faz parte de um fenômeno biológico, desenvolvido a partir da exposição aos raios UV, uso de hormônios exógenos, fatores genéticos, e fármacos que causam fotossensibilização. Sabe-se que a incidência ocorre principalmente em mulheres em idade fértil. A hiperpigmentação trata-se de uma doença da pele que surge após lesão cutânea em decorrência de uma reação inflamatória. Por ser - o melasma e a hiperpigmentação - duas condições relativamente frequentes, e pela frequência com que ressurgem após o tratamento, é de extrema importância conhecê-las a fim de se obter informações relevantes para um tratamento eficaz e sem recidiva. Nesse sentido, o objetivo deste estudo foi realizar uma revisão de literatura sobre melasma e hiperpigmentação contemplando a fisiopatologia e os principais tratamentos utilizados. Para isto, foi desenvolvido uma pesquisa qualitativa de cunho exploratório-descritivo realizada em periódicos internacionais no período de novembro de 2016 a abril de 2017. Os protocolos de tratamento progrediram nos últimos anos, entretanto, o conhecimento da real patogênese do melasma continua insatisfatório e que agentes tópicos e os sistemas que utilizam laser, por vezes induzem a melhora da pigmentação e não a eliminação
total da lesão.


Palavras-chave


melasma; pele; hiperpigmentação; epidemiologia; tratamento

Texto completo:

PDF

Referências


Swalwell H, Latimer J, Haywood RM, Birch-Machin MA. Investigating the role of melanin in UVA/UVB and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells. Free Radic. Biol. Med. 52. p. 626-634. 2012. Doi: 10.1016/j.freeradbiomed.2011.11.019.

Wang, SQ, Balagula, Y, Osterwalder U. Photoprotection: A review of the current and future technologies. Dermatol Ther. 23, p. 31-¬47. 2010. Doi: 10.1111/j.1529-8019.2009.01289.x.

Bolanca I, Bolanca Z, Kuna K, Vukovic A, Tuckar N, Herman R, Grubisic G. Chloasma-the mask of pregnancy. Coll Antropol. 32 (2), p.139-141. 2008.

Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 7, 2010. Doi: 10.1002/14651858.CD003583.pub2.

Zhou LL, Baibergenova A. Melasma: systematic review of the systemic treatment. Inter J of Derm. 2017. Doi: Doi: 10.1111/ijd.13578.

Sheth, VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 65, p. 689-697, 2011. Doi: 10.1016/j.jaad.2010.12.046.

Mahmoud BH; Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, Lim HW, Hamzavi IH. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 130, p. 2092–2097. 2010. Doi: 10.1038/jid.2010.95.

Toyos R, Mcgill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg, 33, p. 41–46. 2015. Doi: 10.1089/pho.2014.3819.

Faurschou A, Togsverd-Bo K, Zachariae C, Haedersdal M. Pulsed dye laser vs. Intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation. Br J Dermatol, 160, p. 359-364, 2009. 10.1111/j.1365-2133.2008.08993.x.

Weiss RA, Ross EV, Tanghetti EA, Vasily DB, Childs JJ, Smirnov MZ, Altshuler GB. Characterization of an optimized light source and comparison to pulsed dye laser for superficial and deep vessel clearance. Lasers Surg Med, 43, p. 92–98, 2011. Doi: 10.1002/lsm.21032.

Ho SG, Chan HH. The Asian dermatologic patiente: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 10, p. 153-168, 2009. Doi: 10.2165/00128071-200910030-00002.

Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, Hexsel D, Im S, Lim J, Lui H et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatolb Venereol. 23 (11), p. 1254-1262. 2009. Doi: 10.1111/j.1468-3083.2009.03295.x.

Rivas S, Pandya AG, Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review. Am J Clin Dermatol. 14 (5), P. 359-376. 2013.Doi: 10.1007/s40257-013-0038-4.

Kim SJ, Park JY, Shibata T, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 41, p. 480-485, 2016. Doi: 10.1111/ced.12835.

Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 46, p. 111-116, 2007. Doi: 10.1016/j.jdermsci.2007.01.009.

Becker S, Schiekofer C, Vogt T, Reichrath J. Melasma: Ein Update zu Klinik, Therapie und Pravention. Der Hautarzt. 68, 120-126. 2017. Doi: 10.1007 / s00105-016-3927-7.

Nouveau S, Agrawal D, Kohli M, Bernerd F, Misra N, Nayak CS. Skin Hyperpigmentation in Indian Population: Insights and Best Practice. Indian J Dermatol. 61(5): 487–495.2016. Doi: 10.4103/0019-5154.190103.

Atoyan RY, Sharov AA, Eller MS, Sargsyan A, Botchkarev VA; Gilchrest BA. Oligonucleotide treatment increases eumelanogenesis, hair pigmentation and melanocortin¬1 receptor expression in the hair follicle. Exp Dermatol. 16, p. 671-67¬7. 2007. Doi:10.1111/j.1600-0625.2007.00582.x.

Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 128, p 853-8¬64. 2007. Doi: 10.1016/j.cell.2006.12.045.

Forestier, S. Rationale for sunscreen development. J Am Acad Dermatol. 58, p. 133-138. 2008. Doi: 10.1016/j.jaad.2007.05.047.

Lupi O, Nunes S, Gomes Neto A, Pericles C. Doenças dermatológicas no Brasil: perfil atitudinal e epidemiológico. An Bras Dermatol. 85, p.5-19, 2010.

Handel AC, Miot LDB, Miot HA. Melasma: a clinical and epidemiological review. An. Bras. Dermatol. 89, p. 771-782, 2014. Doi.org/10.1590/abd1806-4841.20143063.

Ishiy PS, Silva LR, Penha MA, Handel AC, Miot HA. Skin diseases reported by workers from the campus of UNESP Rubião Jr, Botucatu-SP (Brazil). An Bras Dermatol. 89, p. 529-531, 2014.

Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 56, p. 380-382. 2011. Doi: 10.4103/0019-5154.84722.

Hexsel D, Lacerda DA, Cavalcante AS, Machado Filho CA, Kalil CL, Ayres EL, Azulay-Abulafia L, Weber MB, Serra MS, Lopes NF et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol. 53, p. 440-444. 2013. Doi: 10.1111/j.1365-4632.2012.05748.x.

Tamega AA, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 27, p. 151-156. 2013. Doi: 10.1111/j.1468-3083.2011.04430.x.

Videira IF, Moura DF, Magina S. Mechanisms regulating melanogenesis. An Bras Dermatol. 88, p. 76-83, 2013.

Miot LD, Miot HA, Silva MG, Marques ME. Physiopathology of melasma. An Bras Dermatol.84, p. 623-35, 2009. Doi.org/10.1590/S0365-05962009000600008.

Ascenso A, Ribeiro H, Marques HC, Oliveira H, Santos C, Simões S. Is tretinoin still a key agent for photoaging management? Mini Rev Med Chem. 14, p. 629-6¬41. 2014.

Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, Tay YK, Legarda-Montinola F, Tsai RY, Tsai TH et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 159(3):697-703. 2008. Doi: 10.1111/j.1365-2133.2008.08717.x.

Konda S, Geria AN, Halder RM. New horizons in treating disorders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 31, p. 133-13¬9. 2012. Doi: 10.1016/j.sder.2012.03.001.

Hwang JA, Park NH, Na YJ, Lee HK, Lee HJ, Kim YJ, Lee CS. Coumestrol down-regulates melanin production in melan-a murine melanocytes through degradation of tyrosinase. Biol. Pharm. Bull. 40. p. 535-539, 2017. Doi: 10.1248/bpb.b16-00834.

Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effecty of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 27, p. 1035-1039, 2013. Doi: 10.1111/j.1468-3083.2012.04464.x.

Reichel CA, Lerchenberger M, Uhl, B, Rehberg M, Berberich N, Zahler S, Wymann MP, Krombach F. Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature. PLoS One. 6, p. 17229, 2011. Doi: 10.1371/journal.pone.0017229.

Jang WS, Lee CK, Kim BJ, Kim MN. Efficacy of 694¬nm Q¬switched ruby fractional laser treatment of melasma in female Korean patients. Dermatol Surg. 37, p. 1133-11¬40. 2011. Doi: 10.1111/j.1524-4725.2011.02018.x.

Yue, B; Yang, Q; Xu, J; Lu, Z. Efficacy and safety of fractional Q-switched 1064-nm neodymium-doped yttrium aluminum garnet laser in the treatment of melasma in Chinese patients. Lasers in Medical Science. 31, p. 1657-1663. 2016. Doi:10.1007/s10103-016-2034-4.

Cho SB, Kim JS; Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd:YAG laser with low pulse energy. Clin. Exp. Dermatol. 34, p.847-850. 2009. Doi: 10.1111/j.1365-2230.2009.03599.x.

Choi M, Choi JW, Lee SY, Choi SY, Park HJ, Park KC, Youn SW, Huh CH. Low-dose 1064-nm Q-switched Nd:YAG laser for the treatment of melasma. J Dermatolog Treat. 21(4):224-8. 2010. Doi: 10.3109/09546630903401462.

Davis EC, Callender VD. Postinflammatory hyperpigmentation: A review of the epidemiology, clinical features, and treatment options in skin of colors. J Clin Aesthet Dermatol. 3, p. 20-31, 2010.

Callender VD, St Surin-Lord S, Davis EC, Maclin M. Postinflammatory hyperpigmentation: Etiologic and therapeutic considerations. Am J Clin Dermatol. 12, p. 87-99, 2011. Doi: 10.2165/11536930-000000000-00000.

Hourblin V, Nouveau S, Roy N, Lacharriere O. Skin complexion and pigmentary disorders in facil skin of 1204 women in 4 Indian cities. Indian J Dermatol Venereol Leprol. 80, p. 395-401, 2014. Doi: 10.4103/0378-6323.140290.0020

Eimpunth S, Wanitphadeedecha R, Manuskiatti W. A focused review on acne-induced and aesthetic procedure-related postinflammtory hyperpigmentation in Asians. J Eur Acad Dermatol Venereol. 27, p. 7-18, 2013. Doi: 10.1111/jdv.12050.

Ando H, Ichihashi M, Hearing VJ. Role of the ubiquitin proteasome system in regulating skin pigmentation. Int. J. Mol. Sci. 10, p. 4428-4434, 2009.

Del Bino, S; Ito, S; Sok, J; Nakanishi, Y; Bastien, P; Wakamatsu, K; et al. Chemical analysis of constitutive pigmentation of human epidermis reveals constant eumelanin to pheomelanin ratio. Pigment Cell Melanoma Res. 28, p.707-7¬17. 2015. Doi: 10.1111/pcmr.12410.

Del Bino, S; Berberd, F. Variations in skin colour and the biological consequences of ultraviolet radiation exposure. Br J Dermatol. 169, p. 33-40, 2013. Doi: 10.1111/bjd.12529.

Jablonski, N. G; Chaplin, G. Colloquium paper: Human skin pigmentation as an adaptation to UV radiation. Proc Natl Acad SciUSA. 107, p. 8962-8968, 2010. Doi: 10.1073/pnas.0914628107.

Khan MT. Novel tyrosinase inhibitors from natural resources – their computational studies. Curr. Med. Chem. 19. p. 2262-2272, 2012. Doi: 10.2174/092986712800229041.




DOI: http://dx.doi.org/10.14450/2318-9312.v30.e2.a2018.pp85-94

Apontamentos

  • Não há apontamentos.


Direitos autorais 2018 Kledson Lopes Barbosa, Monique Ribeiro Mota Gudes

Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional.

Conselho Federal de Farmácia - CFF

SHIS QI 15 Lote "L" - Lago Sul - Brasília - DF

CEP: 71635-615 - Fone: (61)3878-8751

e-mail:infarma@cff.org.br

Infarma-Ciências Farmacêuticas

ISSN - 0104-0219 (Versão impressa)

ISSN - 2318-9312 (Versão eletrônica)

Indexadores: